Successful treatment of a disseminated Sporothrix schenckii infection and in vitro analysis for antifungal susceptibility testing

Diagnostic Microbiology and Infectious Disease

Volumn 58, Issue 1, 2007, Pages 117-120

  Kohler, Lidiane Meire ^a   Hamdan, Júnia Soares ^a   Ferrari, Teresa Cristina Abreu ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Antifungal drugs; Disseminated sporotrichosis; Osteoarticular sporotrichosis; Sporothrix schenckii; Susceptibility test

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; GENTAMICIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INSULIN; ISONIAZID; ITRACONAZOLE; OXACILLIN; PYRAZINAMIDE; RIFAMPICIN; TERBINAFINE;

ADULT; ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIAL ARTHRITIS; BLOOD CELL COUNT; BONE MALFORMATION; BRAZIL; CASE REPORT; DIABETES MELLITUS; DRUG INHIBITION; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GRANULOMATOUS INFLAMMATION; HISTOPATHOLOGY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; IN VITRO STUDY; KIDNEY FUNCTION; MONARTHRITIS; OSTEOPENIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PUS; SKIN ABSCESS; SKIN DEFECT; SPOROTHRIX SCHENCKII; SPOROTRICHOSIS; SYNOVECTOMY; THORAX RADIOGRAPHY; THYROID FUNCTION; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; UNIVERSITY HOSPITAL; VENEREAL DISEASE REACTION TEST;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DIABETES COMPLICATIONS; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OSTEOARTHRITIS, KNEE; SPOROTHRIX; SPOROTRICHOSIS; TREATMENT OUTCOME;

EID: 34247855084     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.11.002     Document Type: Article

References (25)

1. Appenzeller S., Amaral T.N., Amstalden E.M.I., Bertolo M.B., Neto J.F.M., Samara A.M., and Fernandes S.E.M. Sporothrix schenckii infection presented as monoarthritis: report of two cases and review of the literature. Clin. Rheumatol. 7 (2005) 1-3
2. Bustamante B., and Campos P.E. Endemic sporotrichosis. Curr. Opin. Infect. Dis. 14 (2001) 145-149
3. Bustamante B., and Campos P.E. Sporotrichosis: a forgotten disease in the drug research agenda. Expert Rev. Anti Infect. Ther. 2 (2004) 85-94
4. Casali A.K., and Hamdan J.S. Effect of three azole derivatives on the lipids of different strains of Sporothrix schenckii. Can. J. Microbiol. 43 (1997) 1197-1202
5. -1) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 47 (2004) 62-68
6. Chowdhary G., Weinstein A., Klein R., and Mascarenhas B.R. Sporotrichal arthritis. Ann. Rheum. Dis. 50 (1991) 112-114
7. Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved Standard CLSI Document M27-A2 (2002), National Committee for Clinical Laboratory Standards, Wayne (PA)
8. Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved Standard Document M38-A (2002), National Committee for Clinical Laboratory Standards, Wayne (PA)
9. Ghosh A., Chakrabarti A., Hemashettar B.M., and Maiti P.K. In vitro susceptibility pattern of Sporothrix schenckii strains isolated from three centers in India. Indian J. Med. Res. 113 (2001) 214-220
10. Gordhan A., Ramdial P.K., Morar N., Moodley S.D., and Aboobaker J. Disseminated cutaneous sporotrichosis: a marker of osteoarticular sporotrichosis masquerading as gout. Int. J. Dermatol. 40 (2001) 717-719
11. Howell S.J., and Toohey J.S. Sporotrichal arthritis in South Central Kansas. Clin. Orthop. Relat. Res. 346 (1998) 207-214
12. Jessup C.J., Ryder N.S., and Ghannoum M.A. An evaluation of the in vitro activity of terbinafine. Med. Mycol. 38 (2000) 155-159
13. Kauffman C.A. Sporotrichosis. Clin. Infect. Dis. 29 (1999) 231-237
14. Kauffman C.A., Pappas P.G., McKinsey D.S., Greenfield R.A., Perfect J.R., Cloud G.A., Thomas C.J., and Dismukes W.E. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin. Infect. Dis. 22 (1996) 46-50
15. Kauffman C.A., Hajjeh R., and Chapman S.W. Practice guidelines for the management of patients with sporotrichosis. Clin. Infect. Dis. 30 (2000) 684-687
16. Koç A.N., Uksal U., and Oymak O. Case report. Successfully treated subcutaneous infection with Sporothrix schenckii in Turkey. Mycoses 44 (2001) 330-333
17. Kohler L.M., Monteiro P.C.F., Hahn R.C., and Hamdan J.S. In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine. J. Clin. Microbiol. 42 (2004) 4319-4320
18. Kohler L.M., Soares B.M., Santos D.A., Barros M.E.S., and Hamdan J.S. In vitro susceptibilities of isolates of Sporothrix schenckii to amphotericin B, itraconazole, and terbinafine: comparison of yeast and mycelial forms. Can. J. Microbiol. 52 (2006) 843-847
19. Lortholary O., Denning D.W., and Dupont B. Endemic mycoses: a treatment update. J. Antimicrob. Chemother. 43 (1999) 321-331
20. McGinnis M.R., Pasarell L., Sutton D.A., Fothergill A.W., Cooper Jr. C.R., and Rinaldi M.G. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob. Agents Chemother. 41 (1997) 1832-1834
21. Purvis R.S., Diven D.G., Drechsel R.D., Calhoun J.H., and Tyring S.K. Sporotrichosis presenting as arthritis and subcutaneous nodules. J. Am. Acad. Dermatol. 28 (1993) 879-884
22. Rippon J.W. Sporotrichosis. In: Rippon J.W. (Ed). Medical Mycology: the Pathogenic Fungi and The Pathogenic Actinomycetes. 3rd ed. (1988), Saunders, Philadelphia 277-302
23. Ryder N.S. Activity of terbinafine against serious fungal pathogens. Mycoses 42 (1999) 115-119
24. Smith J.W., Chalupa P., and Hasan M.S. Infectious arthritis: clinical features, laboratory findings and treatment. Clin. Microbiol. Infect. 12 (2006) 309-314
25. Trilles L., Torres B.F., Lazera M.S., Wanke B., Schubach A.O., Paes R.A., Inza I., and Guarro J. In vitro antifungal susceptibility of Sporothrix schenckii in two growth phases. Antimicrob. Agents Chemother. 49 (2005) 3952-3954